Novartis Lescol May Be OTC Switch Candidate, Karabelas Says
Executive Summary
The safety profile of Novartis' HMG-CoA reductase inhibitor Lescol would support an OTC switch, Novartis Pharmaceuticals CEO Jerry Karabelas suggested at a review of the company's 1997 financial results held March 17 in London.